Squamous Cell Carcinoma of the Skin Clinical Trial
Official title:
Carrellizumab Combined With Albumin-binding Paclitaxel in the Treatment of Locally Late Stage or Relapsed Metastatic Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Multicenter, Prospective Clinical Study
Verified date | May 2023 |
Source | Henan Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24 patients with squamous cell carcinoma of the skin, to further confirm the efficacy and safety of Carrellizumab combined with albumin-binding paclitaxel in the treatment of squamous cell carcinoma of the skin.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: Patients =18 years old; ECOG score 0~1, organ function is good; Histologically confirmed first-line treatment for locally advanced or relapsed metastatic squamous cell carcinoma of the skin. There were measurable tumor lesions evaluated by MRI or CT during the 21 days prior to enrollment; If you have received antitumor therapy, the following conditions should be met: 1. The interval between systemic radiotherapy and the first dose in this study was =3 weeks, and the interval between local radiotherapy was =2 weeks; 2. The interval between previous chemotherapy, targeted therapy, biotherapy, endocrine therapy and other antitumor therapies and the first administration in this study was =4 weeks; Normal function of major organs (within 14 days prior to treatment); For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence from sex or use of effective contraceptive methods during treatment and for at least 7 months after the last dose in the study treatment; The patients voluntarily participated in this study and signed the informed consent. Who can be included as judged by the researcher. Exclusion Criteria: Previously received anti-PD-1, anti-PD-L1, anti-PD-L2 drug therapy; Also receiving antitumor therapy in other clinical trials; Had major surgical operations within 4 weeks prior to enrollment, or had not fully recovered from such operations; Serious heart disease or discomfort or concomitant disease that, according to the judgment of the investigator, seriously endangers the safety of the patient or affects the completion of the study; Allergic reactions: Patients who are allergic to the investigational drug or to any investigational drug component in the chemotherapy regimen are not recommended for inclusion. Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or patients of childbearing age who did not want to take effective contraceptive measures during the entire trial period and within 6 months after the last study; Those considered unsuitable for inclusion by researchers. |
Country | Name | City | State |
---|---|---|---|
China | Henan Cancer Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Henan Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | The proportion of tumor volume reduction that reaches the predetermined value and maintains the minimum time limit. | It is estimated to take about 60 months from the start of enrollment to the end of the experiment. | |
Secondary | Progression-Free-Surviva | The time from the start of treatment to the appearance of secondary growth | The estimated time from enrollment to disease progression is about 24 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Active, not recruiting |
NCT06327971 -
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
|
||
Not yet recruiting |
NCT03621462 -
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
|
N/A | |
Not yet recruiting |
NCT04480645 -
CivaDerm(TM) Surface Therapy Pilot Study
|
Early Phase 1 | |
Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
Recruiting |
NCT06014086 -
Intratumoral PH-762 for Cutaneous Carcinoma
|
Phase 1 | |
Completed |
NCT02347813 -
Preventing Squamous Cell Skin Cancer
|
Phase 2 | |
Terminated |
NCT01984892 -
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
|
Phase 2 | |
Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04204837 -
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
Completed |
NCT03894618 -
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
Not yet recruiting |
NCT05246228 -
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
|
||
Completed |
NCT02324608 -
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
|
N/A | |
Recruiting |
NCT02717936 -
Investigation of Desmoplastic Squamous Cell Carcinoma
|
N/A | |
Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05490485 -
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 |